As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise ...

Vertex reported revenues of $2.65 billion in the last reported quarter, representing a year-over-year change of +6.1%. EPS of -$12.83 for the same period compares with $3.89 a year ago.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LONDON, August 07, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 0.26% to $486.11 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0 ...

Vertex reported revenues of $2.65 billion in the last reported quarter, representing a year-over-year change of +6.1%. EPS of -$12.83 for the same period compares with $3.89 a year ago.

Dividend stocks offer long-term investors unique benefits.

Shares of Vertex Pharmaceuticals Inc. VRTX sank 0.55% to $474.29 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.04% ...